| payload |
{"created_at":"2026-04-22T03:03:32.063 {"created_at":"2026-04-22T03:03:32.063787+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:3692f88932944f2b","evidence_event_ids":["evt_a597b637822f"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1563880/0001193125-26-166693.txt","as_of":"2026-04-22T03:03:32.063787+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1563880/0001193125-26-166693.txt","company":"Trevi Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1563880/0001193125-26-166693.txt","article_chars":3591,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_fbd9d0b874d60b6c","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1563880/0001193125-26-166693.txt","content_type":"text/plain","enriched_at":"2026-04-22T03:17:49.168619+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"DEFA14A","final_url":"https://www.sec.gov/Archives/edgar/data/1563880/0001193125-26-166693.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1563880/0001193125-26-166693.txt","source_event_id":"evt_a597b637822f","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"DEFA14A","fp":"b6cb67e45d5cc735","kind":"sec_filing","published_at":"20260421","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-21","2026-04-22","June 2, 2026","June 3, 2026","May 20, 2026","December 31, 2026","2029 Annual Meeting of Stockholders"],"entities":[{"asset_class":"equity","name":"Trevi Therapeutics, Inc.","relevance":"high","symbol":"TRVI","type":"issuer"}],"event_type":"listing","information_gaps":["What specifically changed versus the prior known state is not provided in the extracted text (no prior filing comparison content included).","The document does not include the full proxy statement details; it appears to be an overview/notice of availability and voting items.","No explicit financial guidance or financial implications are stated in the provided text beyond governance/share-authorization items."],"key_facts":["Form type: DEFA14A (Definitive Additional Materials)","Filing relates to Trevi Therapeutics, Inc. 2026 Annual Meeting","Meeting date stated: June 3, 2026","Proxy materials availability/notice: vote by June 2, 2026 11:59 PM ET","Board recommends voting on items 1\u20135","Item 1: Election of one Class I director; nominee listed as Michael Heffernan; term until the 2029 Annual Meeting of Stockholders","Item 2: Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026","Item 3: Advisory approval of compensation paid to named executive officers","Item 4: Approval of the Trevi Therapeutics, Inc. Amended and Restated 2019 Stock Incentive Plan","Item 5: Approval of amendment to Restated Certificate of Incorporation to increase authorized common stock from 200,000,000 to 400,000,000 shares","Filing fee: No fee required (as indicated in the document header)"],"numeric_claims":[{"label":"Authorized common stock (before)","value":"200,000,000 shares"},{"label":"Authorized common stock (after)","value":"400,000,000 shares"},{"label":"Vote deadline","value":"June 2, 2026 11:59 PM ET"},{"label":"Annual meeting date","value":"June 3, 2026"},{"label":"Meeting time","value":"11:00 a.m. Eastern Time"},{"label":"Authorized shares increase ratio","value":"2x"}],"primary_claim":"Trevi Therapeutics, Inc. filed Form DEFA14A (definitive additional materials) for its 2026 annual meeting, with board-recommended proposals including increasing authorized common shares from 200,000,000 to 400,000,000.","relevance_score":0.55,"sentiment":"neutral","source_quality":"high","summary":"Trevi Therapeutics, Inc. filed a definitive additional proxy-related filing (DEFA14A) for its 2026 annual meeting, providing notice/overview of available proxy materials and the board-recommended voting items. The filing includes proposals covering director election, auditor ratification, advisory executive compensation, stock incentive plan approval, and an amendment to increase authorized common shares.","topics":["SEC filing","proxy materials","annual meeting","corporate governance","stock incentive plan","authorized shares amendment"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form DEFA14A \u00b7 Trevi Therapeutics, Inc. \u00b7 Filed 20260421","ticker":"TRVI","tickers":["TRVI"],"title":"TRVI filed DEFA14A","url":"https://www.sec.gov/Archives/edgar/data/1563880/0001193125-26-166693.txt"}}... |